5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The iron-regulated metastasis suppressor N-myc downstream-regulated gene 1 (NDRG1) has been shown to inhibit numerous oncogenic signaling pathways in cancer cells. Recent findings have demonstrated that NDRG1 inhibits the ErbB family of receptors, which function as key inducers of carcinogenesis. NDRG1 attenuates ErbB signaling by inhibiting formation of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) and HER2/HER3 heterodimers and by down-regulating EGFR via a mechanism involving its degradation. Understanding the complex interplay between NDRG1, iron, and ErbB signaling is vital for identifying novel, more effective targets for cancer therapy.

          Related collections

          Author and article information

          Journal
          J Biol Chem
          J. Biol. Chem
          jbc
          jbc
          JBC
          The Journal of Biological Chemistry
          American Society for Biochemistry and Molecular Biology (11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110, U.S.A. )
          0021-9258
          1083-351X
          4 August 2017
          14 June 2017
          : 292
          : 31
          : 12772-12782
          Affiliations
          [1]From the Molecular Pharmacology and Pathology Program, Department of Pathology, Bosch Institute, University of Sydney, Sydney, New South Wales 2006, Australia
          Author notes
          [2 ] Supported by a Peter Doherty post-doctoral fellowship from the National Health and Medical Research Council of Australia, a Cancer Institute of New South Wales Early Career Fellowship, and a grant awarded through the 2014 round of the Priority-driven Collaborative Cancer Research Scheme (Grant 1086449) and co-funded by Cure Cancer Australia Foundation of Australia and Cancer Australia. To whom correspondence may be addressed. Tel.: 61-2-9036-6548; Fax: 61-2-9351-3429; E-mail: zaklina.kovacevic@ 123456sydney.edu.au .
          [3 ] To whom correspondence may be addressed. Tel.: 61-2-9036-6548; Fax: 61-2-9351-3429; E-mail: d.richardson@ 123456med.usyd.edu.au .
          [1]

          Recipient of a Cure Cancer Australia Young Investigator Priority-driven Collaborative Cancer research grant.

          Edited by F. Peter Guengerich

          Article
          PMC5546018 PMC5546018 5546018 R117.776393
          10.1074/jbc.R117.776393
          5546018
          28615452
          61218c7d-912d-4040-8b9c-2a209650fab9
          © 2017 by The American Society for Biochemistry and Molecular Biology, Inc.
          History
          Funding
          Funded by: National Health and Medical Research Council , open-funder-registry 10.13039/501100000925;
          Funded by: National Breast Cancer Foundation , open-funder-registry 10.13039/501100001026;
          Funded by: Cancer Institute NSW , open-funder-registry 10.13039/501100001171;
          Funded by: Cure Cancer Australia Foundation , open-funder-registry 10.13039/501100001184;
          Categories
          Minireviews

          cancer therapy,cell signaling,epidermal growth factor receptor (EGFR),iron,metastasis,NDRG1

          Comments

          Comment on this article